

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-11 (cancelled).

12. (currently amended): A substantially purified polypeptide comprising an amino acid sequence at least ~~85%~~ 90% identical to SEQ ID NO:4, provided said polypeptide comprises amino acids 67-98 of SEQ ID NO:4, and wherein said polypeptide binds IL-10 or IL-22.

13. (previously presented): The polypeptide of claim 12, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO:4.

14. (currently amended): A fusion polypeptide comprising the polypeptide of claim 12 operably linked to a non-CRF2-12 polypeptide.

15. (currently amended): The fusion polypeptide of claim 14, wherein said non-CRF2-12 polypeptide comprises at least one member selected from the group consisting of an Fc region of an immunoglobulin ~~molecules or molecule~~, a FLAG epitope, a HIS tag, and a MYC tag.

16. (original): A pharmaceutical composition comprising the polypeptide of claim 12 and a pharmaceutically acceptable carrier.

Claim 17 (cancelled).

18. (currently amended): A kit comprising in one or more containers at the CRF2-12 polypeptide of claim 1.

Claims 9-70 (cancelled).

71. (previously presented): The polypeptide of claim 12, wherein said polypeptide comprises the polypeptide sequences

MMPKHCL/FLG L/FLI, (SEQ ID NO:13),
FQSRNFHNILH/QWQ A/PG (SEQ ID NO:14),
SI/VYFVQYKM/TYGQS/RQW (SEQ ID NO:15),
TPRFTPWWETKL/IDPPV (SEQ ID NO:16),
LV/LYRVFT/IINNSLEKEQKA/VYEG (SEQ ID NO:17),
RAVEIEG/ALI/TPHSSYCVVAEM/TYQPM (SEQ ID NO:18), and
DRRSP/QRSK/EERCVCQ/EIP (SEQ ID NO:19).

Claim 72 (cancelled).

73. (previously presented): The polypeptide of claim 12, wherein the amino acid sequence of said polypeptide is at least 95% identical to SEQ ID NO:4.

74. (previously presented): The polypeptide of claim 12, wherein the amino acid sequence of said polypeptide is at least 98% identical to SEQ ID NO:4.

75. (previously presented): The polypeptide of claim 12, wherein the amino acid sequence of said polypeptide is at least 99% identical to SEQ ID NO:4.

76. (previously presented): The polypeptide of claim 12, wherein said polypeptide binds IL-10.

77. (previously presented): The polypeptide of claim 12, wherein said polypeptide binds IL-22.

Claims 78-91 (cancelled).